Document is current
Any future updates will be listed below
-
Authors
Pilard, Charlotte
Roncarati, Patrick
Ancion, Marie
Luyckx, Margaux
Renard, Michael
Reynders, Celia
Lerho, Thomas
Poulain, Florian
Bruyere, Diane
Lebeau, Alizee
Hendrick, Elodie
Crake, Rebekah
Peiffer, Raphael
Nokin, Marie-Julie
Peulen, Olivier
Delvenne, Philippe
Hubert, Pascale https://orcid.org/0000-0002-0799-3047
Herfs, Michael https://orcid.org/0000-0002-4382-8997
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03161756 at ClinicalTrials.govnct03792763 at ClinicalTrials.govDocuments that mention this clinical trial
RANKL blockade inhibits cancer growth through reversing the tolerogenic profile of tumor-infiltrating (plasmacytoid) dendritic cells
https://doi.org/10.1136/jitc-2024-010753
CHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanoma.
https://doi.org/10.1200/jco.2023.41.16_suppl.9525
nct03280667 at ClinicalTrials.govDocuments that mention this clinical trial
RANKL blockade inhibits cancer growth through reversing the tolerogenic profile of tumor-infiltrating (plasmacytoid) dendritic cells
https://doi.org/10.1136/jitc-2024-010753
nct02470091 at ClinicalTrials.govDocuments that mention this clinical trial
RANKL blockade inhibits cancer growth through reversing the tolerogenic profile of tumor-infiltrating (plasmacytoid) dendritic cells
https://doi.org/10.1136/jitc-2024-010753
nct03923842 at ClinicalTrials.govDocuments that mention this clinical trial
RANKL blockade inhibits cancer growth through reversing the tolerogenic profile of tumor-infiltrating (plasmacytoid) dendritic cells
https://doi.org/10.1136/jitc-2024-010753
nct01077154 at ClinicalTrials.govDocuments that mention this clinical trial
RANKL blockade inhibits cancer growth through reversing the tolerogenic profile of tumor-infiltrating (plasmacytoid) dendritic cells
https://doi.org/10.1136/jitc-2024-010753
nct02129699 at ClinicalTrials.govDocuments that mention this clinical trial
RANKL blockade inhibits cancer growth through reversing the tolerogenic profile of tumor-infiltrating (plasmacytoid) dendritic cells
https://doi.org/10.1136/jitc-2024-010753
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial
https://doi.org/10.1016/s0140-6736(15)60995-3
Bone Health Outcomes from the International, Multicenter, Randomized, Phase 3, Placebo-Controlled D-CARE Study Assessing Adjuvant Denosumab in Early Breast Cancer
https://doi.org/10.1007/s12325-021-01812-9
nct01077154 at ClinicalTrials.govDocuments that mention this clinical trial
RANKL blockade inhibits cancer growth through reversing the tolerogenic profile of tumor-infiltrating (plasmacytoid) dendritic cells
https://doi.org/10.1136/jitc-2024-010753
The incidence and clinical impact of bone metastases in non-small cell lung cancer
https://doi.org/10.1016/j.lungcan.2015.04.007
nct02129699 at ClinicalTrials.govDocuments that mention this clinical trial
RANKL blockade inhibits cancer growth through reversing the tolerogenic profile of tumor-infiltrating (plasmacytoid) dendritic cells
https://doi.org/10.1136/jitc-2024-010753
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial
https://doi.org/10.1016/s0140-6736(15)60995-3
Bone Health Outcomes from the International, Multicenter, Randomized, Phase 3, Placebo-Controlled D-CARE Study Assessing Adjuvant Denosumab in Early Breast Cancer
https://doi.org/10.1007/s12325-021-01812-9
Documents that mention this clinical trial
RANKL blockade inhibits cancer growth through reversing the tolerogenic profile of tumor-infiltrating (plasmacytoid) dendritic cells
https://doi.org/10.1136/jitc-2024-010753
The incidence and clinical impact of bone metastases in non-small cell lung cancer
https://doi.org/10.1016/j.lungcan.2015.04.007
-
Funding
Funding for this research was provided by:
Fonds De La Recherche Scientifique - FNRS (CDR J.0111.20, MIS F.4520.20)
Leon Fredericq Foundation (Not applicable)
Televie (PDR Televie 7.8505.22)
University of Liege (Crédits Sectoriels de Recherche en Sciences de la, Fonds spéciaux facultaires 2019-2024)
- License Information
